Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series
Down syndrome (DS) is an independent risk factor for severe respiratory syncytial virus (RSV) infection. Palivizumab – passive immunization for RSV – is the only pharmacological measure for preventing severe disease. In most countries, palivizumab is indicated in young children with congenital heart...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-04-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1809265 |